Carla Heise

Medicine · Health Sciences

35h-index9.1kcitations97works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pancreatic and Hepatic Oncology Research(23), Virus-based gene therapy research(17), CAR-T cell therapy research(15), Radiomics and Machine Learning in Medical Imaging(14), Cancer Research and Treatments(13)

Publications97 total

Table S4 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
2023Open Access
Figure S1 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
2023Open Access
Table S3 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
2023Open Access
Figure S2 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
2023Open Access
Table S5 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
2023Open Access
Table S4 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
2023Open Access
Table S1 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
2023Open Access
Table S5 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
2023Open Access
Table S1 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
2023Open Access
Data from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
2023Open Access
Data from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
2023Open Access
Table S2 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
2023Open Access
supplemental figure legend from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
2023Open Access
supplemental figure legend from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
2023Open Access
Table S3 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
2023Open Access
Figure S1 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
2023Open Access
Table S2 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
2023Open Access
Figure S2 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
2023Open Access
Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer
British Journal of Cancer·2016· 49 citedOpen Access
Abstract PD3-04: PAK-1 amplified breast cancer cell lines are preferentially sensitive to PAK inhibition with G-5555
Cancer Research·2016· 1 cited
page 1 of 5Next →

Frequent Co-authors

David H. Kirn(14), Sharon L. Aukerman(6), Rajesh Chopra(6), Satya Dandekar(6), Daniel D. Von Hoff(5), Helen Ye(5), Angelica Williams(4), Adam Sampson-Johannes(4), Kyle J. MacBeth(4), Marion Wiesmann(4), Evelyn N. Garrett(4), Vidya Mamidipudi(4), Ian Ganly(3), Britta Randlev(3), Suzanne Trudel(3), Jayesh Vora(3), Peter Schäfer(3), Christopher J. Miller(3), Manuel Hidalgo(3), Charles H. Halsted(3)